恩瑞格注意事项

Thalassemia is a rare cancer disease that is generally caused by genetic factors. Fortunately, we also have corresponding drugs to choose from for thalassemia. Among them is a treatment drug for thalassemia. Its efficacy far exceeds other similar drugs, and it is currently the most commonly used oral drug for thalassemia. However, many patients who are exposed to this drug for the first time do not know the precautions of Enrig. Let’s take a look at it together.

Myelosuppression: Cytopenias (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) (some fatal) have been reported; patients with preexisting hematological disorders may be at increased risk; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenia; may restart once cause of cytopenia is determined; contraindicated if platelet count <50,000/mm3.

Skin Toxicity: May cause rash (dose related); mild to moderate rash may resolve without interruption of treatment; for severe rash, interrupt and consider restarting with dose escalation and lower doses of oral steroids. Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have also been reported; the risk of other skin reactions including drug reactions with eosinophilia and systemic symptoms cannot be excluded.

Gastrointestinal Events: Gastrointestinal bleeding (including death) may occur; more common in patients with advanced hematological malignancies and/or elderly patients with low platelet counts; discontinue treatment for suspected gastrointestinal bleeding or ulceration. Nonfatal upper GI irritation, bleeding, and ulceration (sometimes complicated by GI perforation, including death) have been reported. Use concomitant medications with caution that may increase the risk of adverse gastrointestinal effects (eg, nonsteroidal anti-inflammatory drugs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of gastrointestinal ulceration/bleeding while taking deferasirox (Desirox).

Auditory Interference: Hearing loss and high-frequency hearing loss have been reported (rarely) with use; perform an auditory test before initiation and periodically (every 12 months) during use; monitor closely and consider dose reduction or treatment interruption if abnormalities occur.